CD Genomics Introduces HLA Typing by Next-generation Sequencing to Its Global R&D Clients

CD Genomics Introduces HLA Typing by Next-generation Sequencing to Its Global R&D Clients
CD Genomics is providing accurate and reliable HLA genotyping service using next-generation sequencing (NGS) technology by generating unambiguous, phase-resolved HLA sequencing results in a single assay.

Immunogenetics specialists at CD Genomics of Shirley, New York have developed a special laboratory test to characterize the genes that encode HLA molecules. The test relies on faster, more comprehensive gene sequencing technology (NGS) to type human leukocyte antigens (HLAs) genes in a single assay.

The new test may delivery results through a more refined assessment of donor compatibility and will expedite the donor selection process from bone marrow registries (for direct clinical application). It also provides an advanced tool for research in immunological diseases, infectious diseases, and pharmacogenomics (for R&D field), which is what CD Genomics serves, which studies the influence of genetic variations on drug efficacy and toxicity.

“The HLA genotyping addresses decades years of problem,” said Aleyn Becker, Ph.D., director of the Immunogenetics Laboratory department in CD Genomics. “Since the initial discovery of HLAs in the early 1950s, it has been difficult to accurately and thoroughly characterize HLA gene sequences. We have now used next-generation sequencing tools to significantly advance HLA typing.”

CD Genomics is providing accurate and reliable HLA genotyping service using next-generation sequencing (NGS) technology by generating unambiguous, phase-resolved HLA sequencing results in a single assay. “This is a new, disruptive technology, with the potential to transform research and clinical practice, in transplantation and other fields,” said Robert Doms, M.D., Ph.D., pathologist-in-chief at The Children’s Hospital of Philadelphia (CHOP) (from a previous comment).

HLA genes are one of the most complex gene families known in the entire human genome. Their gene sequences are extremely polymorphic—highly variable. It’s tough to fully uncover by average typing methods, while current tests often provide ambiguous and limited results through segments of HLA genes typing on the basis of a given sequence. Moreover, a second round of reflexive testing is usually run after the first testing, which certainly increase the money and time to the HLA typing process.

Thanks to the new test, by NGS using various amplification and sequencing is uniquely able to address limitations of traditional Sanger sequencing assays in patients requiring a higher level of HLA allele matching, enabling robust, simple, and high-quality analysis of the key HLA genes. Multiplexing enables large numbers of loci to be sequenced simultaneously during a single experiment.

CD Genomics even developed a new protocol for HLA genotyping and in-house scientists validated the test by comparing its results against previously sequenced data and the results were satisfactory.

CD Genomics is offering the HLA typing service, including genotyping of 11 all HLA loci (HLA-A, B, C, DRB1, DRB3/4/5, DQA1, DQB1, DPA1, and DPB1) to deliver a detailed and comprehensive report. The test is faster, more precise, and costs less than existing testing procedures.

About CD Genomics

CD Genomics is a US-based biotechnology company that offers a worldwide service with its high throughput service to process hundreds of samples at a time. The company can only accept genomic DNA for HLA typing. Its aim is to deliver a high confidence and responsive service to its clients at realistic cost. Besides, the company also provides bisulfite sequencing, snp genotyping, 2b-RAD sequencing.

Media Contact
Company Name: CD Genomics
Contact Person: Dianna Gellar
Email: Send Email
Phone: 6316197922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.cd-genomics.com/